Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul>
<li>Arrowhead Pharmaceuticals has reported its financial and operational performance for the fiscal year ending September 30, 2025, during a conference call.</li>
<li>The company achieved notable milestones, including the FDA approval of REDEMPLO, its first FDA-approved drug.</li>
<li>This approval marks Arrowhead's transition into a commercial-stage company, providing a treatment for familial chylomicronemia syndrome (FCS), a rare condition characterized by extremely high triglyceride levels leading to pancreatitis.</li>
</ul>


Arrowhead Pharmaceuticals has reported its financial and operational performance for the fiscal year ending September 30, 2025, during a conference call.
The company achieved notable milestones, including the FDA approval of REDEMPLO, its first FDA-approved drug.
This approval marks Arrowhead's transition into a commercial-stage company, providing a treatment for familial chylomicronemia syndrome (FCS), a rare condition characterized by extremely high triglyceride levels leading to pancreatitis.


Arrowhead Pharmaceuticals Lands a Blockbuster Novartis Deal—Is This a $2 Billion Game Changer?

Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

<ul><li>On November 25, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for fiscal year 2026 that ended September 30, 2025.</li><li>Following the recent approval of REDEMPLO , Arrowhead is now a commercial-stage company and has drug in channel only a week following approval, which is ahead of schedule.</li><li>Looking ahead to 2026, Arrowhead has a number of important data readouts, including a first look at obesity data for ARO-INHBE and ARO-ALK7 in January 2026 with a more complete data set expected in mid-2026, interim data for ARO-DIMER-PA in summer 2026, initial ARO-MAPT data looking at tau levels in CSF in summer 2026, topline results from SHASTA-3 and SHASTA-4 in 3Q26 with a potential sNDA filing before the end of 2026, and biomarker data for ARO-RAGE possible by the end of 2026 or in early 2027.</li></ul>

On November 25, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for fiscal year 2026 that ended September 30, 2025.Following the recent approval of REDEMPLO , Arrowhead is now a commercial-stage company and has drug in channel only a week following approval, which is ahead of schedule.Looking ahead to 2026, Arrowhead has a number of important data readouts, including a first look at obesity data for ARO-INHBE and ARO-ALK7 in January 2026 with a more complete data set expected in mid-2026, interim data for ARO-DIMER-PA in summer 2026, initial ARO-MAPT data looking at tau levels in CSF in summer 2026, topline results from SHASTA-3 and SHASTA-4 in 3Q26 with a potential sNDA filing before the end of 2026, and biomarker data for ARO-RAGE possible by the end of 2026 or in early 2027.

ARWR: Multiple Data Readouts Ahead in 2026 

<ul><li>On November 18, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced that the U.S. Food and Drug Administration (FDA) approved REDEMPLO (plozasiran) for the treatment of adults with familial chylomicronemia syndrome (FCS).</li><li>Arrowhead has set a wholesale acquisition cost (WAC) for REDEMPLO of $60,000 per year.</li><li>This is approximately 1/10th of the cost of Tryngolza, although Ionis Pharmaceuticals has stated that if approved to treat severe hypertriglyceridemia (SHTG) the price of Tryngolza would be in the $10,000-$20,000/yr range.</li></ul>

On November 18, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced that the U.S. Food and Drug Administration (FDA) approved REDEMPLO (plozasiran) for the treatment of adults with familial chylomicronemia syndrome (FCS).Arrowhead has set a wholesale acquisition cost (WAC) for REDEMPLO of $60,000 per year.This is approximately 1/10th of the cost of Tryngolza, although Ionis Pharmaceuticals has stated that if approved to treat severe hypertriglyceridemia (SHTG) the price of Tryngolza would be in the $10,000-$20,000/yr range.

ARWR: REDEMPLO  Approved by FDA for the Treatment of FCS 

<ul>
<li>Arrowhead Pharmaceuticals recently reported its financial and operational performance for its fiscal Q3 2025, highlighting both opportunities and challenges within the business and market environment.</li>
<li>The company's results reflect a dynamic phase of development across its RNAi-based therapeutics pipeline, milestones in partnerships, and forward momentum in commercialization efforts.</li>
<li>Here is an analysis of the quarter's outcomes, presented in a balanced manner.</li>
</ul>


Arrowhead Pharmaceuticals recently reported its financial and operational performance for its fiscal Q3 2025, highlighting both opportunities and challenges within the business and market environment.
The company's results reflect a dynamic phase of development across its RNAi-based therapeutics pipeline, milestones in partnerships, and forward momentum in commercialization efforts.
Here is an analysis of the quarter's outcomes, presented in a balanced manner.


Arrowhead Pharmaceuticals: Therapeutic Advancements in FCS & SHTG...

<ul><li>On September 2, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global license and collaboration agreement with Novartis for ARO-SNCA, the preclinical siRNA therapy targeting alpha-synuclein for the treatment of various synucleinopathies (e.g., Parkinson's Disease), along with additional collaboration targets that will utilize Arrowhead's TRiM platform.</li><li>Arrowhead will receive an upfront payment of $200 million and is eligible to receive up to $2 billion in potential milestone payments plus royalties on commercial sales.</li><li> In addition, on September 3, 2025, Ionis Pharmaceuticals, Inc. (IONS) announced positive topline results from the Phase 3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyceridemia (sHTG), in which reductions of fasting triglycerides of up to 72% and an 85% reduction in acute pancreatitis events were seen.</li></ul>

On September 2, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global license and collaboration agreement with Novartis for ARO-SNCA, the preclinical siRNA therapy targeting alpha-synuclein for the treatment of various synucleinopathies (e.g., Parkinson's Disease), along with additional collaboration targets that will utilize Arrowhead's TRiM platform.Arrowhead will receive an upfront payment of $200 million and is eligible to receive up to $2 billion in potential milestone payments plus royalties on commercial sales. In addition, on September 3, 2025, Ionis Pharmaceuticals, Inc. (IONS) announced positive topline results from the Phase 3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyceridemia (sHTG), in which reductions of fasting triglycerides of up to 72% and an 85% reduction in acute pancreatitis events were seen.

ARWR: Signs Collaboration Agreement with Novartis with 200 Million Upfront 

United States

Arrowhead Pharmaceuticals, Inc. operates as a biotechnology company. The Company develops medicines that treat intractable diseases by silencing the genes. Arrowhead Pharmaceuticals offers its services in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Arrowhead Pharmaceuticals (ARWR US)

Arrowhead Pharmaceuticals Lands a Blockbuster Novartis Deal—Is This a $2 Billion Game Changer?

Arrowhead Pharmaceuticals has reported its financial and operational performance for the fiscal year ending September 30, 2025, during a conference...

Baptista Research

ARWR: Multiple Data Readouts Ahead in 2026

On November 25, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for fiscal year 2026 that ended September 30,...

Zacks Small Cap Research

ARWR: REDEMPLO Approved by FDA for the Treatment of FCS

On November 18, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced that the U.S. Food and Drug Administration (FDA) approved REDEMPLO ...

Zacks Small Cap Research

Arrowhead Pharmaceuticals: Therapeutic Advancements in FCS & SHTG...

Arrowhead Pharmaceuticals recently reported its financial and operational performance for its fiscal Q3 2025, highlighting both opportunities and...

Baptista Research

ARWR: Signs Collaboration Agreement with Novartis with 200 Million Upfront

On September 2, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global license and collaboration agreement with Novartis for ARO-SNCA,...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)